Continuing to Confront COPD International Patient Survey: Economic Impact of COPD in 12 Countries

Abstract

BackgroundThe Continuing to Confront COPD International Patient Survey estimated the prevalence and burden of COPD across 12 countries. Using data from this survey we evaluated the economic impact of COPD.MethodsThis cross-sectional, population-based survey questioned 4,343 subjects aged 40 years and older, fulfilling a case definition of COPD based on self-reported physician diagnosis or symptomatology. Direct cost measures were based on exacerbations of COPD (treated and those requiring emergency department visits and/or hospitalisation), contacts with healthcare professionals, and COPD medications. Indirect costs were calculated from work loss values using the Work Productivity and Activity Impairment scale. Combined direct and indirect costs estimated the total societal costs per patient.ResultsThe annual direct costs of COPD ranged from $504 (South Korea) to $9,981 (USA), with inpatient hospitalisations (5 countries) and home oxygen therapy (3 countries) being the key drivers of direct costs. The proportion of patients completely prevented from working due to their COPD ranged from 6% (Italy) to 52% (USA and UK) with 8 countries reporting this to be ≥20%. Total societal costs per patient varied widely from $1,721 (Russia) to $30,826 (USA) but a consistent pattern across countries showed greater costs among those with increased burden of COPD (symptoms, health status and more severe disease) and a greater number of comorbidities.ConclusionsThe economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities. Strategies to allow COPD patients to remain in work are important for addressing the substantial wider societal costs.

The economic burden of COPD in a Swedish cohort: The ARCTIC study

“…In agreement with this study, a considerable number of studies have reported that COPD is a significant societal economic burden, associated with increased HCRU and higher health care costs, among COPD population versus control population. [18][19][20][21][22][23][24][25][26][27] As in our observations, previous studies have reported that key drivers for higher direct costs of COPD include inpatient hospitalizations 12,17,22,24,26,28 and increased medication use. 12,17,18,24 Further contributory factors to higher direct costs in COPD patients are comorbidities 17,19,23,27 and hospital admissions resulting from comorbidities.…”

“…12 Identifying strategies aimed at the prevention and early diagnosis of COPD may help patients continue to work and help mitigate costs, such as smoking cessation initiatives in the workplace, greater coordination of COPD management between employers and health care providers, and pulmonary rehabilitation programs. 9,17 Determining indirect costs associated with COPD can be challenging, 9 but it is clear that There are a number of important strengths of this study. The large sample size (including patients across the COPD classification spectrum), PC setting, and real-world study design provide data that are highly reflective of the general population.…”

Indacaterol/Glycopyrronium Combination for COPD

“…Thus, appropriate long-term interventions are recommended to lower the economic burden of COPD [6]. Although the economic burden of COPD is considerable across countries, and requires targeted resources to optimise COPD management encompassing the control of symptoms, prevention of exacerbations and effective treatment of comorbidities [7], the three most important factors in individual patients that determine the economic and societal costs of COPD are always disease severity, presence of frequent exacerbations of disease and the presence of comorbidities, which are common (30-57%) in COPD patients [8].…”

Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease

“…In addition to chronic symptoms, both asthma and COPD are also associated with a tendency to deteriorate in an abrupt or sub-acute manner. These events are usually referred to as “exacerbations” or “attacks” which are serious events - they can be fatal but at the very least have a major impact on patients' quality of life and considerable health economic consequences globally [3,4]. …”